Allarity Therapeutics (ALLR) Net Cash Flow (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Net Cash Flow came in at $15.2 million in Q1 2026, up 79.45% YoY from $8.5 million in Q1 2025, and up 538.61% on a QoQ basis from -$3.5 million in Q4 2025.
Allarity Therapeutics (ALLR) Net Cash Flow (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Net Cash Flow data on file, last reported at $15.2 million in Q1 2026.
- Quarterly Net Cash Flow rose 79.45% year-over-year to $15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 90.88% YoY) and the FY2025 annual result came in at -$4.2 million, down 121.84% from the prior year.
- Net Cash Flow improved to $15.2 million in Q1 2026, from -$3.5 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $19.0 million in Q2 2024 to a low of -$8.1 million in Q2 2025.
- A 5-year average of $804000.0 and a median of -$1.1 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow slumped 1943.8% — and 2025, when it surged 44610.53%.
- Tracing ALLR's Net Cash Flow over 5 years: stood at -$1.5 million in 2022, then gained by 21.45% to -$1.2 million in 2023, then jumped by 189.48% to $1.0 million in 2024, then slumped by 436.25% to -$3.5 million in 2025, then soared by 538.61% to $15.2 million in 2026.
- The last three Net Cash Flow figures came in at $15.2 million (Q1 2026), -$3.5 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - | -2.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.18 Mn |
| Mar 31, 2026 | 15.18 Mn |
| Dec 31, 2025 | -3.46 Mn |
| Dec 31, 2025 | -3.46 Mn |
| Sep 30, 2025 | -1.09 Mn |
| Sep 30, 2025 | -1.09 Mn |
| Jun 30, 2025 | -8.08 Mn |
| Jun 30, 2025 | -8.08 Mn |
| Mar 31, 2025 | 8.46 Mn |
| Mar 31, 2025 | 8.46 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | -575,000.00 |
| Sep 30, 2024 | -575,000.00 |
| Jun 30, 2024 | 19.01 Mn |
| Jun 30, 2024 | 19.01 Mn |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Dec 31, 2023 | -1.15 Mn |
| Dec 31, 2023 | -1.15 Mn |